-
Documentary Film 2006: “Money Talks: Profits Before Patient Safety”
A Closer Look At The Promotion And Sales Tactics Of Big Pharma Industry I recently received an email informing me about writer / director Kathleen Slattery-Moschkau’s independent documentary, Money Talks: Profits Before Patient Safety…
-
Ortho Evra Patch Label Change: Serious Blood Clot Risk Warning Increased
Results From Two Studies Prompt Action By FDA and Johnson & Johnson In September 2006 the FDA and Ortho-McNeil Pharmaceutical — a Johnson & Johnson (J&J) company — announced changes to the Ortho Evra…
-
Natrecor: Is Controversial J&J Heart Failure Drug Harmful Or Harmless?
Scios Announces Study To Address Safety Issues But Results Not Expected For Several Years In the October 1, 2006 issue of the medical journal Pharmacotherapy is an article which emphasizes the need to resolve…
-
New Warning About Severe Liver Problems Due To Ketek
Hepatotoxicity Risks Noted In September 2006 "Dear Doctor" Letter On October 4, 2006 Health Canada issued a MedEffect alert to let doctors and patients know that the drug company Sanofi-aventis Canada is updating its…
-
Providing More Information Can Help Avoid Serious Adverse Drug Reactions (Part of Series: ADRs in US)
Part Four: Doctors Should Be Educating Patients About Compliance With Their Medication Regimen So far in this series we have looked at the extent of serious adverse drug reactions (ADRs) in the U.S. and…
-
Some Recommendations To Reduce Serious Adverse Drug Reactions In The U.S. (Part of Series: ADRs in US)
Part Three: Medication Errors Can Be Reduced By Better Prescribing Methods In our first part of this series, we looked at the extent of serious adverse drug reactions (ADRs) in the U.S., and in…
